<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00763035</url>
  </required_header>
  <id_info>
    <org_study_id>Hundley-2</org_study_id>
    <nct_id>NCT00763035</nct_id>
  </id_info>
  <brief_title>Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)</brief_title>
  <official_title>Comparison of Dobutamine and Regadenoson Stress CMR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma US, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to determine the utility of Regadenoson (Lexiscan)for use as an
      imaging agent with cardiac MR. If found useful, it will help us establish a protocol for
      regadenoson stress MR perfusion (Regadenoson stress test with cardiac MR).The investigators
      will compare regadenoson with dobutamine so each participant will undergo two studies. A
      cardiac MR stress test with regadenoson and with dobutamine. The investigators participants
      will include patients with history of COPD and Asthma, so it will also help us determine
      feasibility of Regadenoson in these patient's subgroups.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Potential participants with COPD/asthma unwilling to participate.
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of procedures</measure>
    <time_frame>1 day</time_frame>
    <description>To compare the time involved during pharmacologic stress testing using regadenoson versus intravenous dobutamine in individuals with moderate to severe chronic obstructive pulmonary disease (COPD)or asthma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ease of Administration of regadenoson versus intravenous dobutamine.</measure>
    <time_frame>1 day</time_frame>
    <description>To compare the ease of administration of regadenoson verses intravenous dobutamine during pharmacologic stress testin in individuals with moderate to severe chronic obstructive pulmonary disease (COPD) or asthma.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Asthma</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <condition>Angina</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A will get Dobutamine Stress test with cardiac MR (CMR). Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B will get Regadenoson stress test with CMR. Both arms will then cross over to the other arm to get the second test. So each participant will undergo two types of testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson, Dobutamine</intervention_name>
    <description>Cross-over design in which each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit and dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Lexiscan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 40 to 85 years with OBSTRUCTIVE AIRWAY DISEASES (ASTHMA AND COPD)
             and a forced expiratory volume (FEV1) &gt; 0.5.

          -  Patients should have a clinical indication to undergo cardiac stress test with
             dobutamine.

        Exclusion Criteria:

          -  Those with pacemakers, defibrillators, functioning neural stimulator devices or other
             implanted electronic devices.

          -  Ferromagnetic cerebral aneurism clips or other intraorbital and intracranial metal.

          -  An allergy to Gadolinium or other severe drug allergies.

          -  Acute myocardial infarction within 3 months.

          -  Moderate or severe aortic stenosis or other significant valvular disease;

          -  Claustrophobia.

          -  High grade (2o or 3o) AV Block.

          -  Closed angle glaucoma.

          -  Participants unable to provide informed consent.

          -  Renal dialysis (subjects with moderate-to-severe renal impairment defined as eGFR &lt; 60
             mL/min.

          -  A contraindication to receipt of dobutamine.

          -  Participants with known coronary artery disease will be included with the exception
             that patients with left main or narrowings &gt;50% in the distributions of the left
             anterior descending, circumflex, and right coronary artery will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William G Hundley, M.D., F.A.C.C., F.A.H.A</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WAKE FOREST UNIVERSITY Baptist Medical Center</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, Lieu HD. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol. 2008 May-Jun;15(3):329-36. doi: 10.1016/j.nuclcard.2008.02.009. Epub 2008 Apr 14.</citation>
    <PMID>18513639</PMID>
  </reference>
  <reference>
    <citation>Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, Mathur V. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol. 2008 May-Jun;15(3):319-28. doi: 10.1016/j.nuclcard.2008.02.013. Epub 2008 Apr 14.</citation>
    <PMID>18513638</PMID>
  </reference>
  <reference>
    <citation>Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H, Mahmarian JJ, Olmsted A, Underwood SR, Vitola J, Wang W; ADVANCE MPI Investigators. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007 Sep-Oct;14(5):645-58.</citation>
    <PMID>17826318</PMID>
  </reference>
  <reference>
    <citation>Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet. 2006;45(12):1201-12.</citation>
    <PMID>17112296</PMID>
  </reference>
  <reference>
    <citation>Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, Mahmarian JJ. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol. 2005 Dec 6;46(11):2069-75. Epub 2005 Nov 9.</citation>
    <PMID>16325044</PMID>
  </reference>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>WILLIAM GREGORY HUNDLEY MD</name_title>
    <organization>Wake Forest University Baptist Medical Center</organization>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Coronary Vessels</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Coronary Disease</keyword>
  <keyword>Ischemic heart disease</keyword>
  <keyword>asthma</keyword>
  <keyword>copd</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dobutamine</mesh_term>
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 27, 2017</submitted>
    <returned>November 29, 2017</returned>
    <submitted>November 30, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

